Literature DB >> 27122756

Effects of Coronary Arterial Injection of Tirofiban on Diabetes Mellitus Complicated with Acute Myocardial Infarction in the Elderly.

Yang Liu1, Heng-Liang Liu1, Guo-Ying Geng1, Ning Ba1, Song-Bin Jing1, Wei Guo1, Zhi-Fang Zhang1.   

Abstract

OBJECTIVE: This work aims to explore the short-term efficacy and safety of coronary arterial injection of tirofiban in elderly diabetic patients complicated with acute myocardial infarction (AMI) who underwent emergency percutaneous coronary intervention (PCI).
METHODS: Ninety-seven elderly diabetic patients complicated with ST-elevation myocardial infarction (STEMI) who underwent emergency PCI were selected and randomized into control (group A, 49 cases) and tirofiban (group B, 48 cases) groups. Another 129 nonelderly diabetic patients (group C) complicated with STEMI who underwent emergency PCI and tirofiban treatment in the corresponding period were also involved for comparison.
RESULTS: Thrombolysis in myocardial infarction 3 (TIMI3) flow was significantly higher in groups B and C than in group A after PCI (p < 0.01). TIMI myocardial perfusion grades (TMPG) 0 to 1 and 2 were distinctly lower (p < 0.01, p < 0.05) and TMPG3 was obviously higher (p < 0.01) in groups B and C than in group A. The average length of hospital stay, post-infarction angina pectoris, severe arrhythmia, and cardiac function Killip III to IV were markedly lower in groups B and C than in group A (p < 0.01, p < 0.05). Meanwhile, mucocutaneous hemorrhage was significantly higher in groups B and C than in group A (p < 0.01).
CONCLUSIONS: Tirofiban effectively improved TIMI flow and TMPG perfusion in elderly diabetic patients complicated with AMI and reduced the incidence of serious complications without increasing the occurrence of severe hemorrhage. KEY WORDS: Acute myocardial infarction; Diabetes mellitus; Emergency percutaneous coronary intervention; Tirofiban.

Entities:  

Year:  2013        PMID: 27122756      PMCID: PMC4805034     

Source DB:  PubMed          Journal:  Acta Cardiol Sin        ISSN: 1011-6842            Impact factor:   2.672


  19 in total

Review 1.  Diabetic specific aspects in antithrombotic therapy in patients with coronary artery disease.

Authors:  S Farhan; T Höchtl; J Wojta; K Huber
Journal:  Minerva Med       Date:  2010-08       Impact factor: 4.806

2.  Outcome of patients presenting with ST elevation myocardial infarct and cardiogenic shock: a contemporary single center's experience.

Authors:  Gabriel Greenberg; Abid Assali; Hanna Assa-Vaknin; David Brosh; Igal Teplitsky; Alexander Battler; Ran Kornowski; Eli I Lev
Journal:  Cardiology       Date:  2012-06-22       Impact factor: 1.869

Review 3.  Antithrombotic therapy in patients with coronary artery disease and with type 2 diabetes mellitus.

Authors:  Serdar Farhan; Thomas Höchtl; Alexandra Kautzky-Willer; Johann Wojta; Kurt Huber
Journal:  Wien Med Wochenschr       Date:  2010-01

4.  Predictors and outcome of grade 3 ischemia in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.

Authors:  Sonja Postma; Ton Heestermans; Jurrien W Ten Berg; Jochem W van Werkum; Harry Suryapranata; Yochai Birnbaum; Christian W Hamm; Arnoud W J van 't Hof
Journal:  J Electrocardiol       Date:  2011 Sep-Oct       Impact factor: 1.438

5.  No association between hemoglobin A1c and in-hospital mortality in patients with diabetes and acute myocardial infarction.

Authors:  Kathryn A Britton; Vikas Aggarwal; Anita Y Chen; Karen P Alexander; Ezra Amsterdam; Elizabeth Fraulo; Paul Muntner; Laine Thomas; Darren K McGuire; Stephen D Wiviott; Matthew T Roe; Ulrich K Schubart; Caroline S Fox
Journal:  Am Heart J       Date:  2011-04       Impact factor: 4.749

6.  Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge.

Authors:  J H Chesebro; G Knatterud; R Roberts; J Borer; L S Cohen; J Dalen; H T Dodge; C K Francis; D Hillis; P Ludbrook
Journal:  Circulation       Date:  1987-07       Impact factor: 29.690

7.  Simultaneous transradial coronary and renal in stent restenosis treatment in diabetic patient with NSTEMI complicated by hypertensive emergency.

Authors:  Francesco Summaria; Roberto Patrizi; Enrico Romagnoli; Marina Mustilli; Adolfo Pagnanelli
Journal:  Med Arch       Date:  2012

8.  [Hyperglycemia at admission and outcome in elderly patients with acute ST segment elevation myocardial infarction underwent primary percutaneous coronary intervention].

Authors:  Hong-jie Chi; Da-peng Zhang; Xin-chun Yang; Zhong-su Yang; Yuan Xu
Journal:  Zhonghua Xin Xue Guan Bing Za Zhi       Date:  2009-07

9.  Glycoprotein IIB/IIIA inhibitor to reduce postpercutaneous coronary intervention myonecrosis and improve coronary flow in diabetics: the 'OPTIMIZE-IT' pilot randomized study.

Authors:  Giovanni Paolo Talarico; Marta Brancati; Francesco Burzotta; Italo Porto; Carlo Trani; Maria De Vita; Daniel Todaro; Maura Giammarinaro; Antonio Maria Leone; Giampaolo Niccoli; Felicita Andreotti; Mario Attilio Mazzari; Giovanni Schiavoni; Filippo Crea
Journal:  J Cardiovasc Med (Hagerstown)       Date:  2009-03       Impact factor: 2.160

Review 10.  Defining the role of platelet glycoprotein receptor inhibitors in STEMI: focus on tirofiban.

Authors:  Arnoud W J van 't Hof; Marco Valgimigli
Journal:  Drugs       Date:  2009       Impact factor: 9.546

View more
  1 in total

1.  Efficacy and safety of different doses of tirofiban combined with ticagrelor on diabetic patients with AMI receiving in emergency percutaneous coronary intervention (PCI).

Authors:  Yang Liu; Hengliang Liu; Zhenxuan Hao; Guoying Geng; Qi Chen; Wenjie Han; Kailong Jia; Yuxin Zhou
Journal:  Int J Clin Exp Med       Date:  2015-07-15
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.